Navigation Links
Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
Date:12/9/2012

Phase I/II study and administered an oral dose of the proteasome inhibitor combined with lenalidomide and dexamethasone for up to 12, 28-day cycles, followed by maintenance therapy with MLN9708 every 28 days until disease progression. Primary objectives in Phase I included safety, maximum tolerated dose, and recommended Phase II dose. In Phase II, primary objectives included complete remission and very good partial response (VGPR, measured by a 90% or greater reduction in abnormal myeloma proteins in the blood).

In Phase I, the maximum tolerated dose was determined as 2.97 mg/m2 and recommended Phase II dose was selected as 2.23 mg/m2, which was later converted to a 4.0 mg/m2 dose based on encouraging results related to the body's ability to tolerate the drug. In Phase II, the investigators observed an overall response rate of 92 percent with 55 percent of patients reaching VGPR or better, including 23 percent with a complete remission. As the treatment cycles progressed, the rate and depth of response increased.

Minor adverse events, such as fatigue, nausea, and rash, were noted in approximately 40 percent of patients. Serious adverse events were minimal and primarily consisted of decreased blood counts, nausea and vomiting, diarrhea, rash, and electrolyte disturbances. One patient died from pneumonia while on treatment, and seven patients discontinued treatment due to different side effects.

"As targeted therapies continue to evolve, we are now shifting our efforts to focus on making them safer and producing them in more convenient forms for patients. MLN9708 is a great example of how to accomplish this goal," said Shaji K. Kumar, MD, lead author and Professor of Medicine and Consultant in Hematology at the Mayo Clinic in Rochester, Minn. "We are now planning ongoing studies to examine this drug in combination with other myeloma drugs in Phase II and Phase III clinical trials. Once approved for treatment of myeloma, this drug will al
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Researchers develop novel 3-D culture system for inflammatory breast cancer
2. ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours
3. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
4. Novel mechanism through which normal stromal cells become cancer-promoting cells identified
5. Novel breast screening technology increases diagnostic accuracy
6. UNC, Vanderbilt discover a new live vaccine approach for SARS and novel coronaviruses
7. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
8. Novel treatment strategies for epilepsy
9. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
10. Researchers ID potential patient population who may benefit from novel anti-platelet treatment
11. Undertreatment of common heart condition persists despite rapid adoption of novel therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... (PRWEB) August 30, 2014 One of the ... era is the gluten-free diet. Originally meant for sufferers of ... a catchall for people who are looking to get healthier ... not only is this kind of information erroneous, it also ... problems because of a drastic change in their food ...
(Date:8/30/2014)... 30, 2014 LiveStreamingFitness.com, a company dedicated to ... healthy lifestyle resources, is proud to announce it has been ... at home fitness solutions by ABC’s Good Morning America. ... on ABC’s Good Morning America, “Live Streaming Fitness is the ... your day by streamlining your workout…to boot camp at Life ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 “In 2013, a ... The Jones Firm says in a recently released article on ... person was injured in an auto accident every 12 minutes, ... minutes,” they continue. “Based on the 2013 statistics, between now ... vehicle collision.” , The threat of an auto accident is ...
(Date:8/30/2014)... Boston, MA (PRWEB) August 30, 2014 ... and nurse practitioner locum tenens company , announces ... open September 1, 2014. Barton Associates is headquartered in ... Enfield, CT; Keene, NH; and Jupiter, FL. ... response to the increasing demand for healthcare providers. The ...
(Date:8/30/2014)... The first multidisciplinary recommendations on the management of ... are published today in EP Europace . ... the European Heart Rhythm Association (EHRA), the Acute ... of Percutaneous Cardiovascular Interventions (EAPCI), all of the ... of the task force, said: "Sudden cardiac death ...
Breaking Medicine News(10 mins):Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2Health News:LiveStreamingFitness.com is New Trend In Fitness 2Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Barton Associates Announces New Office Location in Austin, TX 2Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2
... blood clot that develops deep in the vein. It can ... ,People who require prolonged bed rest are vulnerable ... patients in intensive care and patient on catheters are at ... in critically ill patients , a small pulmonary embolism, which ...
... high levels of amino acid are associated with an ... been // associated with an increased risk of heart ... to be associated with homocystinuria, a rare disease characterized ... high levels have also been found to be associated ...
... consisting of periods of growth (anagen), regression (catagen), ... activation of ?-catenin in // telogen-phase adult hair ... Scientists have discovered that the transient activation of ... growth. ,Previous work has implicated Wnt/?-catenin ...
... Not all vitamins may be good for you. A new ... antioxidant vitamins, such as // E, C and beta carotene, ... ,Some studies have shown that vitamin E prevented the ... cells. Thus, the liver destroyed fewer of the bad lipoproteins. ...
... new type of stent that releases medication appears safe ... heart disease patients, // a process known as restenosis. ... drug everolimus. The drug acts by inhibiting cell reproduction ... similar drug-eluting stents, the one used in this study ...
... a recent study neurosurgeons say they are now convinced ... ,Studies in the past have suggested wearing helmets during ... the risk of skull base and cervical-spine (or neck) ... findings prompted researchers to study whether helmets harm or ...
Cached Medicine News:Health News:New Hair in 15 Days Could Now Be A Possibility Say Researchers 2
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely eradicated ... generation ago are returning. Measles was declared eliminated in ... 2014 as of August 15—the highest incidence in 20 ... health department declared whooping cough a problem of ... getting sick and dying from these preventable diseases—in part ...
(Date:8/29/2014)... -- ChemImage will present a workshop focused on hyperspectral ... Science Society,s 22 nd International Symposium on ... .  Forensic Scientists will be in attendance ... can bring to examination procedures. ... Development at ChemImage, will host a workshop during ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... The Department of Justice, on behalf of the U.S. Food ... permanent injunction against generic drug manufacturer Ranbaxy in the ... filed against Ranbaxy Laboratories, Ltd., an Indian corporation; its ... Dale Adkisson, senior vice president, head of global quality, ...
... Fine Chemicals LLC (AFC), a wholly owned subsidiary of ... today that is has been granted Registration as a ... Agency (DEA). AFC has been involved in ... under a Researcher,s License from the DEA.  Recent facilities ...
Cached Medicine Technology:Department of Justice files consent decree of permanent injunction against Ranbaxy 2Department of Justice files consent decree of permanent injunction against Ranbaxy 3Department of Justice files consent decree of permanent injunction against Ranbaxy 4AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing 2AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing 3AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing 4
... contains primers and a FAM-labeled probe that ... gene. In addition, this ASR contains primers, ... internal control sequence. This ASR requires an ... Red reporter dyes such as the Cepheid ...
...
Reptilase-Time from Bothrops atrox...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Medicine Products: